EGFR and pancreatic neoplasm: Gore et al. [80] reported that combinatorial targeting of TGFβRI with LY2157299 and EGFR/HER2 with lapatinib suppresses lymphangiogenesis and metastasis in a syngeneic orthotopic pancreatic cancer model.